Chagas Barriers Treatment

Chagas disease (CD) remains one of the most neglected illnesses in the world, with estimates indicating 5.7 million infected people in Latin and Central America. Currently, there are many barriers that patients with CD have to overcome to obtain a diagnosis, adequate treatment, and appropriate follow-up. One of the main ones is the high rate of underdiagnosis and consequently of patients treated. It is estimated that less than 10% of patients are diagnosed and that less than 1% are treated. Furthermore, to date, there is no "reliable" method that allows measuring therapeutic efficacy. During the last 15 years, researchers from the São Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) have developed numerous projects that have evidenced the high number of patients in an endemic area in the north of the State of Minas Gerais, in addition to providing valuable information on the natural history of CD, the rate of progression to cardiomyopathy and its relationship with antibody levels. A great key to the success of such initiatives has been their strategic articulation with primary health care, which has made it possible to have large cohorts of patients accompanied for more than 10 years. Therefore, it is intended in this project to apply all this knowledge and articulation to identify methodologies and tools that allow overcoming existing barriers. The results obtained will make it possible to increase the number of diagnosed patients to whom treatment will be offered and identify strategies and biomarkers that make it possible to improve patient follow-up and help evaluate new treatment candidates.

Existing samples:

  • Chagas disease

Contact Information

Email:
juliliborges2@gmail.com
Telephone:
55 11 30617041
Address:

Av Eneas Carvalho de Aguiar,470 Cerqueira Cesar
São Paulo
05403000
Brazil

Last Updated: 01/30/2024


Annual Statistics

Year Internal External
Access Requests received Access requests approved Access Requests received Access requests approved
2015 N/A N/A N/A N/A
2016 N/A N/A N/A N/A
2017 N/A N/A N/A N/A
2018 N/A N/A N/A N/A
2019 N/A N/A N/A N/A
2020 N/A N/A N/A N/A
2021 N/A N/A N/A N/A
2022 N/A N/A N/A N/A
2023 N/A N/A N/A N/A
2024 N/A N/A N/A N/A